NHS Cancer Waiting Times Hit Record High

More than 300,000 cancer patients in England are currently waiting longer than the NHS 62-day target to begin treatment following an urgent referral, according to the latest figures published by NHS England — the highest number recorded since performance targets were formally introduced. Health officials and oncology specialists warn that the delays, compounded by diagnostic workforce shortfalls and sustained post-pandemic pressure on services, risk worsening outcomes for patients whose cancers are most responsive to early intervention.

Where the Waiting Time Crisis Stands

The 62-day standard — which requires patients referred urgently by a GP with suspected cancer to begin treatment within two calendar months — has not been met nationally since before the pandemic, according to NHS England data. Officials said performance has deteriorated year on year, with the most recent figures showing the largest gap between target and actual performance since record-keeping began under this framework.

For context, the NHS also operates a 28-day Faster Diagnosis Standard, introduced to ensure patients receive a definitive cancer diagnosis or an all-clear within four weeks of referral. That target is also currently being missed for approximately one in five patients in some trust areas, data show.

Which Cancer Types Face the Longest Delays

Waiting time performance varies significantly by tumour type. Urology cancers — including prostate and bladder cancer — consistently show the longest waiting times, with NHS England data indicating that fewer than 60% of urology patients are treated within the 62-day window in several regions. Lung cancer pathways have also experienced sustained pressure, partly due to demand from the national lung health check programme, which has increased the volume of patients requiring follow-up CT imaging and specialist assessment. Colorectal and gynaecological cancer pathways are similarly strained, officials said.

Regional Disparities

Performance is not uniform across England. NHS trusts in the South East, Yorkshire and the Humber, and the East of England have reported some of the worst recorded breaches of the 62-day standard, according to NHS England's trust-level data. London and the North West have shown marginally better performance, though both regions remain below the 85% operational target. Health equity researchers have noted that patients in areas of higher deprivation are disproportionately affected by diagnostic delays, compounding existing inequalities in cancer outcomes. (Source: NHS England)

The Diagnostic Bottleneck

A central driver of the waiting time crisis is capacity in diagnostic services rather than treatment slots alone. Endoscopy, CT scanning, MRI, and pathology services are all operating at or beyond capacity, specialists say, creating backlogs that delay the point at which patients can be referred from urgent suspected cancer pathways to active treatment teams.

Workforce Shortfalls in Radiology and Pathology

The Royal College of Radiologists has previously reported a shortfall of more than 1,900 clinical radiologists in England, a gap that directly affects the speed with which imaging results can be reported. Pathology services face similar pressures, with histopathology — the laboratory analysis required to confirm most cancer diagnoses — experiencing recruitment and retention difficulties across NHS trusts. Without a confirmed histological diagnosis, patients cannot formally begin treatment under standard care protocols, meaning diagnostic delays translate directly into treatment delays. The broader NHS workforce crisis, covered in related reporting on NHS waiting lists and the deepening GP crisis, is a systemic factor across multiple cancer pathways.

Impact on Patient Outcomes

The clinical consequences of delayed cancer diagnosis and treatment are well-established in peer-reviewed literature. Research published in The Lancet found that for many solid tumours — including breast, bowel, and lung cancer — stage at diagnosis is the single most powerful predictor of survival. Delays that allow a cancer to progress from stage two to stage three or four substantially reduce the likelihood of curative treatment and significantly increase overall treatment cost and complexity.

What the Evidence Shows About Delay and Mortality

A landmark analysis published in the BMJ, drawing on data from across England and five other high-income countries, quantified the mortality cost of treatment delays. The analysis found that across all cancer types studied, each four-week delay was associated with a roughly 10% increase in the hazard of death. For cancers where surgery is the primary curative modality — including early-stage colorectal, lung, and kidney cancer — delays beyond eight weeks were associated with significantly worse five-year survival outcomes. The authors cautioned that these figures represent population-level associations and should not be applied mechanically to individual clinical decisions, but they underscore the importance of reducing systemic delays at scale. (Source: BMJ)

Despite the current pressures, it is important to note that NHS cancer survival rates have improved substantially over the past two decades. Reporting on NHS cancer survival rates reaching a record high and separately on NHS cancer survival rates hitting a decade high provides important context: earlier investment in screening, better treatments, and improved surgical techniques have contributed to long-term improvements even as short-term waiting time performance has declined.

Government and NHS Response

NHS England officials have acknowledged that the 62-day standard is not currently being met and have outlined a series of commitments under the NHS Long Term Workforce Plan and the Cancer Recovery Plan. These include expansion of Community Diagnostic Centres — standalone facilities designed to increase imaging and endoscopy capacity outside of busy acute hospital sites — as well as investment in artificial intelligence tools to assist radiologists in reporting high-volume scans more rapidly.

The Department of Health and Social Care has said it remains committed to returning to the 85% 62-day standard, though officials have not specified a firm timeline for achieving compliance. Health charities and patient groups have called for a more specific and accountable delivery plan, arguing that aspirational commitments without measurable milestones have repeatedly failed to improve performance in previous years.

The Role of Primary Care Referrals

GP referral behaviour is also a factor in the pathway. Research commissioned by NHS England found that a proportion of cancers are still diagnosed through emergency presentation — meaning patients arrive at accident and emergency departments with advanced disease rather than being identified earlier through primary care. Officials said increasing the proportion of cancers diagnosed through planned, GP-initiated pathways is a key objective of the NHS Cancer Strategy. The pressures on general practice that affect this are discussed in related coverage of NHS waiting times and GP shortages. (Source: NHS England)

What Patients Should Know: Recognising Cancer Symptoms

Public health bodies including the World Health Organization and NHS England emphasise that early presentation remains one of the most effective individual actions in improving cancer outcomes. NICE guidelines specify a range of symptoms that should prompt urgent GP consultation and may qualify for a two-week-wait cancer referral. Patients are advised not to delay seeking assessment due to concern about adding to NHS pressures, as early referral remains clinically important.

• Unexplained or persistent weight loss without dietary change
• A lump or swelling that is new, growing, or persistent
• Unexplained bleeding — including blood in urine, stool, vomit, or coughing
• Persistent cough lasting more than three weeks, or a change in a longstanding cough
• Unexplained fatigue that does not resolve with rest
• Changes in bowel habits lasting more than three weeks
• Difficulty swallowing or persistent indigestion
• A sore or ulcer that does not heal within three weeks
• Unexplained pain that is new and persistent
• Changes in the appearance of a mole — including size, shape, colour, or bleeding

The WHO recommends that any symptom on this list lasting more than three weeks should be discussed with a clinician. In England, patients have the right to request an urgent two-week-wait referral from their GP if a clinician considers cancer possible, and those who feel their concerns have not been addressed may seek a second opinion. (Source: WHO, NICE)

The Broader Context: A System Under Pressure

Cancer waiting time performance cannot be separated from the wider pressures bearing on NHS acute services. Elective care backlogs, emergency department crowding, and staff vacancy rates across clinical specialties all affect the operational capacity of trusts to run cancer pathways efficiently. The interplay between these pressures is explored in coverage of NHS waiting lists reaching a record high amid GP shortages, which details the upstream effects of primary care strain on secondary and tertiary services.

Analysts at the Health Foundation and the King's Fund have both published assessments concluding that meeting the 62-day cancer standard at scale will require sustained capital investment in diagnostic infrastructure, a materially larger clinical workforce, and structural reform of patient pathways — changes that are unlikely to be fully realised within a short timeframe. For patients currently in or approaching cancer pathways, health officials said the most important steps remain prompt presentation to a GP with any concerning symptoms, engagement with screening programmes where eligible, and direct communication with their clinical team if they have concerns about their referral status. Early action, the evidence consistently shows, remains the most powerful lever available at the individual level.